Under active development. Data is being added and corrected on an hourly basis.

← Back to Peptides
Tesamorelin structure

Tesamorelin

Growth Hormone
Approved Research
90%
Low Risk
1/5

Dosing Protocol

Typical Dose 2 mg
Range 1 - 2 mg
Maintenance 2 mg daily

Pharmacokinetics

Half-Life 38 min
Onset 10 min
Peak 30 min
Duration 2.0 hrs
Bioavailability 90%
Primary Route Subcutaneous

Administration

Routes Subcutaneous
Injection Sites Abdomen
Needle Gauge 27G
Syringe Type Standard
Timing Morning, Fasted

Reconstitution

Diluent Sterile Water
Volume 2.1 mL
Stability 14 days refrigerated
Vial Sizes 1, 2 mg

Special Instructions

FDA-approved for HIV lipodystrophy. Inject into abdomen only. Do not inject into scar tissue.